Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma 2020-11-18 07:39
GDC-0084 Progress Update: On Track for Phase II Commencement in 2017 2017-08-22 12:06
Board Review of Business Operations and Governance 2017-08-14 11:02
Progress Update on Cantrixil(TM) (TRXE-002-1) Development 2017-08-07 11:03
Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure 2017-03-10 09:21
Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program 2017-03-06 18:54
Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma 2016-10-31 11:54
Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma 2016-10-31 11:40
Conversion of Convertible Notes 2016-09-14 12:07
US FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in Ovarian Cancer 2016-09-12 11:00
Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer 2016-08-11 13:59
Novogen Patent Covering Anisina(TM) Has Proceeded to Grant 2016-06-14 08:30
Novogen Provides Update On Development Of Cantrixil 2016-05-02 10:43
Novogen Receives R&D Tax Incentive Cash Refund 2016-03-17 10:27
Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant 2016-02-19 14:18
Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed 2016-02-05 15:31
Novogen Appoints Dr James Garner as Chief Executive Officer 2015-12-10 06:02
Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial 2015-11-24 08:38
Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia 2015-11-12 08:04
Novogen Applies for Long-term Options Listing 2015-09-30 10:52
1 2 3